InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,712.80
(
0.41%
)
Dow Jones
39,387.76
(
0.00%
)
Brent Oil
84.19
(
0.28%
)
Bitcoin
63,269.58
(
0.34%
)
Post# of 458747
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JB3729

Send PM Follow Ignore
Followers 82
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

JB3729

Re: scottsmith post# 56863

Monday, 03/14/2016 11:07:40 AM

Monday, March 14, 2016 11:07:40 AM

Post# of 458747
I believe that an A2-73 Plus patent would have extended the duration of A2-73's protection, when combined with donepezil.

Long term, I think Anavex's plan is to gain FDA approval for A2-73 for Alzheimer's Disease. Then attempt to replace A2-73 with A3-71 which has patent protection until at least 2033.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!